RSS Feeds
Misoprostol and Nonsteroidal Anti-Inflammatory Drugs
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
TO THE EDITOR:
We read with interest Dr. Levine's recent editorial, in which he stated, “… I would prescribe low doses of NSAIDs such as ibuprofen and nabumetone, which induce less gastropathy” [1].
A randomized, endoscopist-blinded, 12-week study compared the relative effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the mucosa of the esophagus, stomach, and duodenum in elderly patients treated for osteoarthritis [2]. Patients were randomly assigned to receive ibuprofen, 600 mg four times daily (n = 53); ibuprofen, 600 mg four times daily, plus misoprostol, 200 µg four times daily (n = 58); or nabumetone, 1000 mg daily (n = 58). One significant ulcer (> 5 mm in size with measurable depth) occurred with nabumetone, and no significant ulcers occurred with ibuprofen plus misoprostol. However, eight significant ulcers occurred in the group receiving ibuprofen alone. Roth and colleagues [2] concluded that nabumetone has an ulcerogenic potential equal to that of ibuprofen plus misoprostol but is significantly less ulcerogenic than ibuprofen alone.
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
- Copyright ©2004 by the American College of Physicians
